Acadia Pharmaceuticals Inc (ACAD)

NASD · Healthcare · Biotechnology · USA

Acadia Pharmaceuticals Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.

Acadia Pharmaceuticals is a biopharmaceutical company with two core franchises treating neurological and rare diseases. Its commercial products include NUPLAZID for hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE for Rett syndrome treatment. The company develops additional product candidates targeting conditions such as Alzheimer's disease psychosis and other neurological disorders, serving patients globally.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Acadia Pharmaceuticals Inc stock.

Our verdict on ACAD

Slightly undervalued: intrinsic value $21.87 per share, market price $18.32, margin of safety 16.2% (as of 2026-11-17).

Discounting its cash flows at 9.6% (average of 3 methods) values the shares at $21.87; the price of $18.32 is 16% below that value.

ETFs with the most weight in ACAD

17 more funds hold it; the full list is part of the paid plan.

More on ACAD

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than ACAD in Biotechnology

17 more in this industry show a wider margin of safety.

Is ACAD undervalued or overvalued?

ACAD is slightly undervalued (as of the 2026-11-17 close). Discounting its cash flows at 9.6% (average of 3 methods) values the shares at $21.87; the price of $18.32 is 16% below that value.

What is the intrinsic value of ACAD?

$21.87 per share (as of the 2026-11-17 close), against a market price of $18.32. That is a margin of safety of 16.2%. The value is the average of the 3 valuation methods that apply to this company, recomputed every night after the US close.